Based on the ODYSSEY Outcomes and FOURIER Trials, which patient populations, including individuals with T2D, do you believe should be targeted for PCSK9 inhibitors?

Based on the ODYSSEY Outcomes and FOURIER Trials, which patient populations, including individuals with T2D, do you believe should be targeted for PCSK9 inhibitors?

Get Credit

Based on the ODYSSEY Outcomes and FOURIER Trials, which patient populations, including individuals with T2D, do you believe should be targeted for PCSK9 inhibitors?

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical Cardiology, Interventional Cardiology, Lipid Medicine, Atherosclerosis and Diabetes Specialist's Perspective

Presenter

Deepak Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC

Deepak Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC

Executive Director of Interventional Cardiovascular ProgramsBrigham and Women’s HospitalHeart and Vascular CenterProfessor of Medicine, Harvard Medical SchoolBoston, USA